ConductScience.org, home

Paper2013113

Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.

Schwendener RA and 3 others. Cancer Chemother Pharmacol, 1991. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Papers, record 2013113. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2013113

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1991
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1
iCite
Revised in PubMed
2026-10-10
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schwendener RAR A
2Fiebig HHH H
3Berger MRM R
4Berger DPD P

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MitoxantroneMajor topic
Animals
Bone Marrow
Drug Carriers
Female
Half-Life
Humans
Leukemia L1210
Liposomes
Male
Mammary Neoplasms, Experimental
Membranes
Mice
Mice, Inbred ICR
Mice, Inbred Strains
Mice, Nude
Neoplasm Transplantation
Neoplasms, Experimental
Phosphatidic Acids
Tissue Distribution

Source PubMed

Download CSV of topics

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13473685High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.Semin Oncol1987https://conductscience.org/library/papers/3473685PubMed
23165047Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.Cancer1988https://conductscience.org/library/papers/3165047PubMed
36700415[Growth of human cancers in the thymus aplastic nude mouse].Med Welt1984https://conductscience.org/library/papers/6700415PubMed
42491964Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2491964PubMed
56733844Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6733844PubMed
63470546Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38.J Natl Cancer Inst1987https://conductscience.org/library/papers/3470546PubMed
72543512Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2543512PubMed
87225141Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.Biochem Pharmacol1981https://conductscience.org/library/papers/7225141PubMed
93412115Membrane lipid alteration: effect on cellular uptake of mitoxantrone.Lipids1988https://conductscience.org/library/papers/3412115PubMed
104019117Mitoxantrone as a first-line treatment of advanced breast cancer.Invest New Drugs1985https://conductscience.org/library/papers/4019117PubMed
116690066Mitoxantrone: an active new agent in the treatment of advanced breast cancer.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6690066PubMed
123370735Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3370735PubMed
132939941The preparation of large volumes of homogeneous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer.Cancer Drug Deliv1986https://conductscience.org/library/papers/2939941PubMed
143521429Mitoxantrone: a new anticancer drug with significant clinical activity.Ann Intern Med1986https://conductscience.org/library/papers/3521429PubMed
15427798Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.Cancer Res1979https://conductscience.org/library/papers/427798PubMed
166347376Mitoxantrone (novantrone): a review of experimental and early clinical studies.Cancer Treat Rev1983https://conductscience.org/library/papers/6347376PubMed
172974073The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.J Microencapsul1988https://conductscience.org/library/papers/2974073PubMed
183413128Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.Proc Natl Acad Sci U S A1988https://conductscience.org/library/papers/3413128PubMed
193768370Liposome-mediated delivery of pteridine antifolates to cells in vitro: potency of methotrexate, and its alpha and gamma substituents.Biochim Biophys Acta1986https://conductscience.org/library/papers/3768370PubMed
203370737Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3370737PubMed

See all 45 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
31236772Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.Pharm Res2019https://conductscience.org/library/papers/31236772PubMed
9083333Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.Br J Cancer1997https://conductscience.org/library/papers/9083333PubMed
9010021Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice.Br J Cancer1997https://conductscience.org/library/papers/9010021PubMed
7880728Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.Br J Cancer1995https://conductscience.org/library/papers/7880728PubMed
7506649Liposomes as carriers of cancer chemotherapy. Current status and future prospects.Drugs1993https://conductscience.org/library/papers/7506649PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2013113

GET https://conductscience.org/api/papers/v1/2013113/references?page=2